Above is an overview of recent industry M&A activity. For additional information, see the charts below or follow the link to the left to download complete transaction tables broken out by industry subsectors.
See below for additional information about industry trading comps and transaction relevant articles from the past week.
Tanner Pharma Group Signs Distribution Agreement With Nephcentric LLC
The agreement names Tanner as a distributor of ure-Na in areas outside the U.S., Canada, and Middle East where the product is not yet registered.
Tanner Pharma Group ("Tanner"),
a global provider of integrated specialty access solutions, has announced the signing of a distribution agreement with Nephcentric LLC ("Nephcentric"), a developer and marketer of evidence based therapeutic options for people with kidney disease and metabolic disorders. The agreement names Tanner as a distributor of ure-Na (Urea 15g) in areas outside of the United States, Canada, and the Middle East where the product is not yet registered. ure-Na (Urea 15g) is a Medical Food for the management of hyponatremia. The distribution will be managed by TannerGAP, Inc. ("TannerGAP"), a wholly owned subsidiary of Tanner Pharma Group. TannerGAP offers turn key global access solutions for the distribution of products from markets of supply to markets of demand.
Aralez Pharmaceuticals To Enter Into Purchase Agreements To Sell Substantially All Assets
Transactions to be valued at an aggregate of U.S. $250 million
Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) ("Aralez" or the "Company") Aralez Pharmaceuticals Inc. announced today that it intends to enter into purchase agreements with two separate stalking-horse purchasers to sell its main operating businesses: an agreement to sell its VIMOVO® royalties and Canadian operations to Nuvo Pharmaceuticals Inc. ("Nuvo") in a transaction valued at U.S.$110 million and an agreement to sell its TOPROL-XL® Franchise to its secured lender, certain funds managed by Deerfield Management Company, L.P., in a transaction valued at U.S.$140 million. The Company is also engaged in ongoing efforts to sell the assets not being sold in either of the proposed transactions and intends to wind down its operations following the consummation of the sales. The letters of intent signed with each of Nuvo and the Company's secured lender included the material terms of each of the proposed transactions.
Below are summaries and charts with the past week's transactions from the different healthcare sectors. For a detailed table showing data for each industry transaction click on any of the charts or use the download link above. Total transaction values are provided in USD millions.